Arimidex, Buy Arimidex, Arimidex Side Effects
images
Home       |      Services       |      Resources       |      Site Map       |      Contact Us
                MENU
icon Arimidex side effects
icon Arimidex for man
icon Arimidex anastrozole side effects
icon Arimidex tamoxifen
icon Generic arimidex
icon Arimidex atac tamoxifen
icon Arimidex medication
icon Arimidex joint pain
icon Breast cancer arimidex
icon

Arimidex and weight gain

icon Arimidex hair loss
icon Arimidex drug effects more side
icon Anastrozole arimidex man
icon Arimidex bone pain
icon Arimidex drug prescribed
   
  Featured Links
 
icon Anabolic Steroids
icon Buy Steroids
icon Buy Steroids
icon Steroid Abuse
   
   
Arimidex drug prescribed:

Arimidex is an aromatase inhibitor (sometimes called an AI). It is usually provided in 1MG tabs or in liquid form. The drug works in a non-steroid form by inhibiting the aromatase enzyme which convertstestosterone and other androgens into estrogen. This means that there is less arimidexestrogen tocause female pattern fat deposits, gyno, and water retention. In medicine, Arimidex isutilized to treat prostate cancer. In sports chemistry, the drug has been employed as ameans of preventing excessive estrogenic side effects during AAS use and to aid increating a harder appearing musculature for competitive bodybuilders. Unlike Nolvadex,which simply block estrogen receptor-sites, this drug prevents or reduces estrogenproduction. Though some estrogen presence is noted as necessary for AAS to reach fulleffectiveness, too much can cause a layer of fat, water retention, and breast tissue growthpotentially with tumors called gynecomastia or bitch tits. Arimidex has a 75-85%aromatization inhibition rate.


Males who experienced excessive aromatization of AAS or who were extremelyestrogen sensitive usually utilized a dosage of 0.5-3.0 mg daily. In fact, most realizedexcellent estrogen control with only 0.5mg/d (mg daily). Women usually showedexcellent lean appearances (even in their legs) with 0.5-1.0 mg daily. Arimidex has a veryshort active-life so 0.5 mg dosages were often taken 2-6 times daily at equal intervals.Stacking 10-30 mg of Nolvadex with 1.0 mg of Arimidex has resulted in a near "0"estrogen activity situation regardless of the AAS protocol utilized. Directly following anAAS cycle, estrogen control has also become a problem (during periods intended for reestablishingHPTA function). In this case, the dosage was reduced from a higher startingdosage to a low dosage that was continued for 7-14 days after AAS discontinuance. Thisprotocol was considered necessary to assure clearing of AAS induced estrogen build-up.



Reported Characteristics

Active-Life: 4-6 hours
Drug Class: Aromatase inhibitor (Oral)
Average Reported Dosage: 0.5-3.0 mg daily
Acne: No
Water Retention: None
Liver Toxic: Yes dosage dependent
Decreases HPTA function: Increases it.



TRADE NAMES:

ARIMIDEX .25 MG TABS (International Pharmaceuticals)
ARIMIDEX 1mg TABS (British Dragon)
 
Cancer as a Disease, Not a Death Sentence
For a small but growing number of patients, once-fatal cancer has become a chronic disease.


PROSPECTS; A Tale of Two Drugs Hints at Promise for Genetic Testing
Dr Stephen Liggett, University of Maryland School of Medicine heart failure specialist, and Dr Michael Bristow of University of Colorado Health Sciences Centers lead research on bucindolol, beta blocker thought to treat heart failure, that shows it is most effective on patients with specific gene variant; hold that many drugs could be better targeted for patients and that genetic material should be collected as part of clinical drug trials to help in matching patient with drug; research is publ...


Quality of Life Found Equal With 2 Breast Cancer Drugs
Tamoxifen and raloxifene have an equal overall effect on quality of life among women with breast cancer, but their side effects vary.


Sorting Out Pills to Reduce Breast Cancer Risk
It's not clear that women concerned strictly about breast cancer will line up for the preventative benefits of the drug raloxifene.


Breast Cancer Research
Boston University Prof Alan B Cohen letter holds that April 19 editorial about new study comparing raloxifene and tamoxifen in prevention of breast cancer, appropriately challenges current Food and Drug Administration policy, which approves new drugs for marketing based solely on comparison with placebos in clinical trials


Therapies Cut Death Risk, Breast-Cancer Study Finds
Combining standard chemotherapy and hormone treatment can halve the risk of death from breast cancer for at least 15 years, a study found.


Certain Type of Breast Cancer Drug Shows Better Result in Study
Researchers report that class of hormone-blocking drugs called aromatase inhibitors is more effective than tamoxifen in preventing breast cancer recurrence in women past menopause; say findings suggest that aromatase inhibitors should replace tamoxifen as first line of treatment for postmenpausal women with breast cancer


Another Way to Fight Breast Cancer Relapse
Most women who have breast cancer and are past menopause should take a type of hormone-blocking drug known as an aromatase inhibitor to prevent cancer recurrence, experts said Monday.


Radiation Is Questioned in Breast Cancer Surgery After Age 70
Radiation treatments routinely given after surgery to remove small breast tumors may not be necessary for women over age 70 if they are taking the cancer drug tamoxifen.


Heeding a Call to Test Breast Cancer Treatments
When Sister Mary Andrew Matesich's cancer returned, her doctor's suggestion of entering a clinical trial intrigued her.


COMPANY NEWS; F.D.A. TO SPEED REVIEW OF NOVARTIS CANCER DRUG
Novartis says Food and Drug Administration will speed its review of company's request for approval of new use of Femara, drug used to treat breast cancer, to reduce risk of relapse after women complete therapy with tamoxifen


Test May Aid Chemotherapy Decisions
A new genetic test can help predict whether breast cancer will recur, providing a way to help women decide whether they need chemotherapy, researchers in Texas said on Thursday.


Study Suggests Switching Drugs Could Aid Breast Cancer Patients
Study comparing two drugs designed to prevent recurrence of breast cancer finds that women who switch from standard drug tamoxifen to newer treatment, anastrozole or Arimidex, fare better than those continuing on tamoxifen; Italian researcher Dr Francesco Boccardo presents results at San Antonio Breast Symposium


New Drug Regimen Greatly Cuts Risk of Recurring Breast Cancer
A study found that a drug treatment can markedly reduce the chance that breast cancer will recur in postmenopausal women.


F.D.A. Tells Barr to Delay Cancer Drug
Barr Laboratories must delay introducing its own version of AstraZeneca's Tamoxifen cancer drug, the Food and Drug Administration said.


Home    |    Services   |    Resources  |    Site Map  |    Contact Us
Copy rights reserved by iarimidex.com